NPR program examines Brazil's antiretroviral program, efforts to collaborate with other countries to fight HIV

NPR's "Tell Me More" on Thursday included a discussion with Brazil's HIV/AIDS program director Mariangela Simao. Simao discussed progress in Brazil's no-cost antiretroviral program and the country's efforts to collaborate with Portuguese-speaking countries in Africa on HIV prevention.

According to Simao, 180,000 Brazilians are receiving no-cost antiretroviral treatment, one of the highest numbers among developing countries. An additional 15,000 to 17,000 people annually enroll in the treatment program, Simao said. Brazil aims to achieve universal access to HIV treatment and to make the country's antiretroviral program sustainable in the long term, Simao added.

Simao also discussed Brazil's efforts to provide materials on HIV/AIDS and collaborate on prevention activities with Portuguese-language speaking countries in Africa. According to Simao, the United Nations, Brazilian government, and health and women's affairs ministries from Portuguese-speaking countries met in Brazil last month to discuss ways to address HIV/AIDS and gender issues (Corley, "Tell Me More," NPR, 6/12).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows safety of kidney transplants among those with HIV infections